Press releases

Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2013


Click here to download the full 2013 interim results statement.
Click here to download the 2013 interim results presentation.

Oxford, UK – 29 August 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces its unaudited interim results for the six months ended 30 June 2013.  Year to date highlights include:

•Manufacturing: alliances in vector manufacturing, research, development and IP

Novartis development and manufacturing collaboration announced in May:
- Oxford BioMedica to manufacture a lentiviral vector encoding CTL019
- Expected to generate between £2.5 million to £4 million of income over initial 12 months

•Development: LentiVector® platform evolution supports next generation of products
Sanofi programmes:
- Positive StarGen™ DSMB review of first three patient cohorts (n=12) in Phase I/IIa trial
- UshStat® video selected to showcase theme of “Life-changing Research” at ARVO 2013
Mayo Clinic, Rochester (USA) collaboration:
- Glaucoma-GT pre-clinical evaluation demonstrated further positive data
- Long-term gene expression out to five months
- Non-clinical programme for enhanced product construct on track
New product opportunities:
- Pre-clinical evaluation of new product opportunities ongoing

Industry collaborations: 5T4 tumour antigen platform
TroVax® investigator-led Phase II programme:
- Phase II study in mesothelioma underway at Velindre Cancer Centre, Wales

•Revenue of £2.1 million (H1 2012 £4.4 million), including £0.6 million from Novartis collaboration
•Research & Development costs of £6.8 million (H1 2012 £6.9 million)
•Net loss of £5.9 million (H1 2012 £4.9 million)
•Net cash burn2 of £7.3 million (H1 2012 £7.8 million)
•Net cash3 at 30 June 2013 of £6.9 million (31 December 2012: £14.1 million)

•TroVax® Phase II prostate cancer data and pre-treatment biomarker analyses published in Cancer Immunology, Immunotherapy
•Oxford BioMedica announced as winner of Technology Strategy Board funding award
•US$1 million milestone payment from Pfizer triggered in August
- Phase I clinical trial for 5T4-targeted antibody therapy underway
•Net cash3 at 26 August 2013 of £6.8 million (excluding US$1 million to be received from Pfizer)

1.Unaudited results
2.Net cash used in operating activities plus sales and purchases of non-current assets
3.Cash, cash equivalents and available for sale investments

John Dawson, Chief Executive Officer at Oxford BioMedica, said: “Oxford BioMedica remains at the forefront of UK biopharmaceutical development and innovation and we are proud to be working with industry leaders such as Novartis, Sanofi and Pfizer, and prestigious centres around the world on pioneering gene-based therapies.

“Being an innovator in the field presents its challenges, however we believe our industry alliances provide independent validation of our research, development and manufacturing capabilities, and strong foundations upon which to build a financially self-sustainable company.  Our LentiVector® gene delivery technology underpins a promising pipeline of product candidates and we continue to seek new sources of revenue, including grant funding awards, in order to maximise our opportunity to bring life-changing treatments to patients.” 

An analyst briefing will be held at 09:30am BST on Thursday, 29 August 2013 at the offices of Consilium Strategic Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.  There will be a simultaneous live conference call and the presentation will be available on the Company’s website at

Please visit the website approximately 10 minutes before the conference call, at 09:20am BST, to download the presentation slides.  Conference call details:

Participant dial-in: +44 (0) 1452 555566
Conference ID: 35449628

An audio replay file will be made available shortly afterwards via the Company's website on the “Media/Download centre/Webcasts and audio” section.   Alternatively, you may listen to the replay by dialling the following number:

Dial-in for replay (available until 05-09-2013): +44 (0) 1452 550000
Conference ID: 35449628


Notes to editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000

Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700